%0 Journal Article
%T ERCC1在Ⅱ期结直肠癌中的表达及其临床意义<br>Expression and its clinical significance of ERCC1 in stage Ⅱ colorectal carcinoma
%A 梁
%A 晶
%A 吴文安
%A 白
%A 璐
%A 刘慧娟
%A 杨怡萍
%A 王
%A ？`
%A 张智策
%A 李
%A 涛
%J 西安交通大学学报(医学版)
%D 2017
%R 10.7652/jdyxb201706022
%X 摘要：目的 探讨核苷酸切除修复交叉互补基因1(ERCC1)在Ⅱ期结直肠癌中的表达及其临床意义。方法 采用免疫荧光技术检测56例Ⅱ期结直肠癌术后癌组织中ERCC1的表达，SPSS 13.0统计软件进行数据分析。结果 癌组织中ERCC1表达低于正常肠黏膜组织(P＝0.01)，复发或转移患者ERCC1表达低于未出现患者(P＝0.002)，T3患者ERCC1表达高于T4患者(P＝0.044)，差异均有统计学意义。ERCC1表达与总生存率和无病生存率均呈正相关(P＝0.000；P＝0.000)。ERCC1高表达组中，接受含奥沙利铂方案辅助化疗患者和未接受化疗的患者5年总生存率和无病生存率差异均无统计学意义(P=0.351；P=0.465)；ERCC1低表达组中，接受含奥沙利铂方案辅助化疗患者5年总生存率和无病生存率均高于未接受化疗的患者，差异均有统计学意义(P=0.015；P=0.02)。ERCC1(P=0.031)和复发转移(P=0.009)是影响总生存率的独立预后因素，复发转移(P=0.000)是影响无病生存率的独立预后因素。 结论 ERCC1是影响Ⅱ期结直肠癌患者总生存率的独立预后因素；ERCC1低表达患者预后差，但可从含奥沙利铂方案的辅助化疗中获益。<br>ABSTRACT: Objective To investigate the expression and clinical significance of excision repair cross complementing gene 1 (ERCC1) in colorectal carcinoma of stage Ⅱ and its clinical significance. Methods We collected 56 cases of stage Ⅱ postoperative colorectal carcinoma tissue and detected ERCC1 expression with immunofluorescence technique. Statistical analysis was made with SPSS13.0 software. Results ERCC1 expression was obviously lower in stage II postoperative colorectal carcinoma tissue than in normal tissue (P=0.01). In cancer tissue, ERCC1 expression in patients with relapse or metastasis was significantly lower than in those without (P=0.002); ERCC1 expression in patients with T？？3 was significantly higher than those with T？？4 (P＝0.044). ERCC1 expression had a positive correlation with the overall survival (OS) and disease-free survival (DFS) (both P＝0.000). In the group of high ERCC1 expression patients, five-year OS rate and DFS rate between patients who had received oxaliplatin-based adjuvant chemotherapy and those who did not have no significant difference (P=0.351; P=0.465). In the group of low ERCC1 expression patients, five-year OS rate and DFS rate of patients who received oxaliplatin-based adjuvant chemotherapy were significantly higher than those of patients who did not (P=0.015, P=0.02). ERCC1 (P=0.031) and relapse or metastasis (P=0.009) were independent factors affecting OS; relapse or metastasis (P=0.000) was an independent factor affecting DFS. Conclusion ERCC1 is an independent factor affecting the OS of patients with stage Ⅱ colorectal carcinoma. Patients with low ERCC1 expression have poor prognosis, but they can benefit from oxaliplatin-based adjuvant chemotherapy
%K 结直肠癌
%K 核苷酸切除修复交叉互补基因1(ERCC1)
%K 术后辅助化疗
%K 预后&lt
%K br&gt
%K colorectal carcinoma
%K excision repair cross complementing gene 1 (ERCC1)
%K adjuvant chemotherapy
%K prognosis
%U http://yxxb.xjtu.edu.cn//oa/darticle.aspx?type=view&id=201706022